Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

GAITHERSBURG, Md.--(BUSINESS WIRE)--Jun 4, 2007 - GenVec, Inc. (Nasdaq: GNVC) announced today that updated preliminary safety and efficacy data from the clinical development program of its lead product TNFerade(TM) was presented in a poster session on gastrointestinal cancers at the annual meeting of American Society for Clinical Oncology in Chicago, IL by Dr. Mitchell Posner, of the University of Chicago. An oral discussion of the posters then concluded the Saturday morning viewing session.

The poster presentation, Multi-Center, Phase 2/3, Randomized, Controlled Clinical Trial using TNFerade(TM) Gene Delivery Combined with Chemoradiation in Patients with Locally Advanced Pancreatic Cancer (LAPC), covered the most recent data from GenVec's Pancreatic Cancer Clinical Trial, known as the PACT study. This multi-center, randomized and controlled trial will evaluate the safety and efficacy of TNFerade plus standard of care, versus standard of care alone, in 330 subjects with locally advanced pancreatic cancer. The study is powered to detect a 20% absolute increase in the primary efficacy endpoint (12 month survival) compared to standard of care (SOC) chemoradiation. Patients are randomized in a 2:1 ratio to TNFerade plus standard therapy, or standard therapy alone.

Data presented included information from a planned interim analysis of results based on the first 51 patients treated with TNFerade, as well as a risk/benefit assessment performed in conjunction with evaluating the merits of resuming the option of administration of the agent by endoscopic ultrasound (EUS). Secondary outcome measures of overall survival, objective response, resections and other lab parameters were included. No analysis was performed on the primary efficacy endpoint (12 month survival).

Regarding Overall Survival, median survival was 19.3 months for patients in the TNFerade + SOC arm versus 11.1 months for patients receiving s
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014  The ... grow, with the publication of two papers this past ... Otolaryngology – Head and Neck Surgery , finds ... objective and subjective measures of sleep disordered breathing, leading ... the reduction in obstructive sleep apnea severity and improvement ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... ) filings continue to grow in federal court, ... U.S. Food & Drug Administration (FDA) have voted ... treat low testosterone in men be subjected to ... risks. According to a report published on September ...
(Date:9/20/2014)... The festival season is coming soon. The high-end ... luxurious cocktail dresses . A lot of sophisticated women ... launch a new promotion for its high quality clothes. Now, ... price, from 20 to 71 percent off. , The ... They are provided in many fashionable colors. Mary, the company’s ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), ... new website. The new site provides the latest ... for customers. Here, people can find a lot ... Also, it has recommended some excellent web hosting ... the great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ...
(Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
(Date:9/20/2014)... 2014 The Arizona Advanced Manufacturing ... celebrating National Manufacturing Day by opening its doors to ... and additive manufacturing labs will be offered between 10 ... MCC’s Southern and Dobson campus (1833 W. Southern Ave, ... D. , The AzAMI at MCC was established in ...
Breaking Medicine News(10 mins):Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... of hysteria are often ticked off, by physicians, ... However, researchers from Sunnybrook Health Sciences Centre, disagree that ... emotional instability. ,Brain scans helped to detect ... in three women with hysteria. Technically, hysteria is ...
... U.S. hospitals spend roughly $20 billion to treat the nearly ... inpatient care//, according to a new report by HHS’ Agency ... billed for almost half of all injury cases, and more ... uninsured. The federal report also found: ,? Broken ...
... in Ithaca and Weill Cornell Medical College in New ... biomarkers// in cerebrospinal fluid that acts as a neurochemical ... living with Alzheimer’s disease. ,The research will ... Annals of Neurology. ,Right now, physicians rely ...
... India, has come up with another project. This scheme named ... to cost Rs 342.81-crores. ,The Global Fund aids ... will also be spent for reducing the transmission of HIV ... including antiretroviral therapy to those already infected. ,There ...
... facial is the new entrant to skin treatment in Jaipur.// ... skin or other beauty related problems, dry fruit facial is ... ,"This is a new technique and more and more ... has benefited several of my clients. It nourishes the skin ...
... hit upon a good device to utilize original stem cells ... of bioengineers at Carnegie Mellon University's Robotics Institute and stem ... have put together a method to organize the growth of ... Carnegie Mellon along with a team, spent time on mouse ...
Cached Medicine News:Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 2Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: